online database

在线数据库
  • 文章类型: Journal Article
    阿曼苏丹国拥有丰富的生物多样性,特别是在药用植物中,并在传统医疗保健实践中起着至关重要的作用。然而,关于这些植物的丰富知识分散在各种文献中,这对研究人员来说是个挑战,从业者,和公众获得全面的信息。因此,集中式的可用性,用户友好的在线数据库来编目阿曼的药用植物是非常重要的。PlantMedOman在这里介绍,目前拥有186项记录有助于加强学术研究,支持药物发现研究,促进药用植物的保护,并提高对阿曼民族医学遗产的认识。
    The Sultanate of Oman has a rich biodiversity, particularly in medicinal plants, and plays a crucial role in traditional healthcare practices. However, the wealth of knowledge about these plants is scattered across various literature, making it challenging for researchers, practitioners, and the public to access comprehensive information. Therefore, the availability of a centralized, user-friendly online database to catalog Oman\'s medicinal plants is of great importance. PlantMedOman presented here, which currently holds 186 records helps to enhance academic research, support drug discovery studies, promote the conservation of medicinal plants, and foster greater awareness of Oman\'s ethnomedicinal heritage.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    由NIH于2015年创建,通用数据元素(CDE)存储库提供免费的在线访问,以搜索和使用通用数据元素。此工具有助于确保一致的数据收集,节省时间和资源,并最终提高数据集的准确性和互操作性。此列的目的是提供数据库的概述,讨论为什么它对研究人员和健康科学相关的图书馆员很重要,并审查网站的基本布局,包括示例搜索,将演示如何使用它。
    Created by the NIH in 2015, the Common Data Elements (CDE) Repository provides free online access to search and use Common Data Elements. This tool helps to ensure consistent data collection, saves time and resources, and ultimately improves the accuracy of and interoperability among datasets. The purpose of this column is to provide an overview of the database, discuss why it is important for researchers and relevant for health sciences librarians, and review the basic layout of the website, including sample searches that will demonstrate how it can be used.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    蛋白质结构测定与预测,活性位点检测,和蛋白质序列比对技术都利用有关蛋白质结构和结构关系的信息。对于膜蛋白,然而,在突出和绘制这种结构相似性的可用在线工具之间的协议有限。此外,没有可用的资源提供四元和内部对称性的系统概述,以及它们相对于薄膜的方向,尽管这些特性可以为膜蛋白功能和进化提供关键见解。这里,我们描述了通过结构和对称性分析的膜蛋白百科全书(EncoMPASS),从序列的角度来关联已知结构的完整膜蛋白的数据库,结构,和对称性。可以通过Web界面访问EncoMPASS,它的内容可以很容易地下载。这允许用户不仅专注于特定的蛋白质,还要研究膜蛋白的结构和进化的一般性质。
    Protein structure determination and prediction, active site detection, and protein sequence alignment techniques all exploit information about protein structure and structural relationships. For membrane proteins, however, there is limited agreement among available online tools for highlighting and mapping such structural similarities. Moreover, no available resource provides a systematic overview of quaternary and internal symmetries, and their orientation relative to the membrane, despite the fact that these properties can provide key insights into membrane protein function and evolution. Here, we describe the Encyclopedia of Membrane Proteins Analyzed by Structure and Symmetry (EncoMPASS), a database for relating integral membrane proteins of known structure from the points of view of sequence, structure, and symmetry. EncoMPASS is accessible through a web interface, and its contents can be easily downloaded. This allows the user not only to focus on specific proteins, but also to study general properties of the structure and evolution of membrane proteins.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    背景:前胶原-赖氨酸,2-酮戊二酸5-双加氧酶(PLOD)是一组可以介导赖氨酰羟化为羟赖氨酸并参与稳定胶原蛋白形成的酶。有证据表明,PLOD参与了肿瘤进展的步骤,包括扩散,入侵,和转移。然而,关于PLOD1/2/3在肺癌中的功能的信息有限.在这项研究中,我们研究了PLODs在肺腺癌(LUAD)和肺鳞癌(LUSC)患者中的表达模式和预后价值.
    方法:使用Oncomine数据库和UALCAN分析非小细胞肺癌(NSCLC)中PLOD家族成员的mRNA表达水平。通过Kaplan-Meier绘图仪数据库研究了PLOD的预后价值。我们搜集33例肺癌患者进一步验证PLODs的表达谱和预后价值。使用Kaplan-Meier方法进行生存曲线,并进行对数秩检验以评估生存率的差异。根据GSE31210的数据集,我们进行了单因素和多因素分析,以确定PLOD是否是生存的独立预后指标.同时,我们调查了突变,基于cBioPortal的PLOD的潜在生物学功能和免疫相关性,分别为Metascape和TIMER数据库。
    结果:我们发现NSCLC组织中PLODs的mRNA和蛋白表达水平高于正常肺组织。PLOD1/2/3的高表达与LUAD的低生存率显著相关,但与LUSC无关。此外,GSE31210数据集显示,PLOD1和PLOD3是LUAD患者无复发生存期和总生存期(OS)的独立危险因素.我们观察到LUSC患者的PLODs改变率很高,PLOD的遗传改变与有利OS显著相关。此外,我们观察到PLODs与肺癌的肿瘤免疫显著相关.对京都基因和基因组百科全书(KEGG)途径的富集分析表明,PLODs的功能集中在细胞周期上,DNA复制,和LUAD的糖酵解/糖异生。
    结论:这些结果表明PLODs在肺癌中高表达,可能是合适的预后标志物。
    BACKGROUND: Procollagen-lysine, 2-oxoglutarate 5-dioxygenases (PLODs) are a group of enzymes that can mediate the hydroxylation of lysyl to hydroxylysine and participate in the formation of stabilized collagen. Evidence has demonstrated that PLODs are involved in the steps of tumor progression, including proliferation, invasion, and metastasis. However, limited information is available on the function of PLOD1/2/3 in lung cancer. In this study, we investigated the expression patterns and prognostic values of PLODs in patients with lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC).
    METHODS: The Oncomine database and UALCAN were used to analyze the mRNA expression levels of PLOD family members in non-small cell lung cancer (NSCLC). The prognostic values of PLODs were investigated by the Kaplan-Meier Plotter database. We collected 33 patients with lung cancer to further verify the expression profiles and prognostic values of PLODs. The Kaplan-Meier method was used to perform survival curves, and the log-rank test was performed to evaluate the differences in survival. According to the GSE31210 databset, univariate and multivariate analyses were performed to identify whether PLODs were independent prognostic indicators for survival. Meanwhile, we investigated the mutations, potential biological functions and immune relevance of PLODs on the basis of the cBioPortal, Metascape and TIMER databases respectively.
    RESULTS: We found that the mRNA and protein expression levels of PLODs in NSCLC tissues were higher than those in normal lung tissues. High PLOD1/2/3 expression had significant relevance to poor survival in LUAD but not in LUSC. In addition, the GSE31210 dataset showed that PLOD1 and PLOD3 were independent risk factors for relapse-free survival and overall survival (OS) in LUAD. We observed a high alteration rate of PLODs in LUSC patients, and the genetic alterations of PLODs had significant relevance to favorable OS. Furthermore, we observed that PLODs were significantly associated with tumor immunity in lung cancer. The enrichment analysis of the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway showed that the functions of the PLODs focused on cell cycle, DNA replication, and glycolysis/gluconeogenesis in LUAD.
    CONCLUSIONS: These results indicated that PLODs were highly expressed in lung cancer and may be suitable prognostic markers.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    当前的研究是一项跨学科的努力,旨在通过蛋白质印迹开发疾病或病症的临床前蛋白质研究的必要工具。在数字化转型和开放获取原则的时代,一个名为East-WestBlot(https://rancs-lab)的基于云的交互式数据库。shinyapps.io/WesternBlots)的设计和开发。建立在Rshiny平台上的在线交互式主题数据库,便于对特定主题进行系统的文献检索,以下是TBI临床前模型中蛋白质调节的蛋白质印迹研究。该工具通过数据可视化技术总结了现有的公开知识,并易于访问关键数据元素和与研究本身的链接。该应用程序编译了PubMed索引的蛋白质印迹研究的关系数据库,标记为HHS公共访问,报告由创伤性脑损伤的液体冲击损伤模型提出的下游蛋白质法规。开发的工具的承诺包括朝着实施3R的原则(替换,reduction,和改进)用于人道实验,在报告特征方面培养可重复研究的先决条件,为基础科学中更具协作性的实验设计铺平道路,并呈现当前公开可用知识的最新和总结观点。
    The current research is an interdisciplinary endeavor to develop a necessary tool in preclinical protein studies of diseases or disorders through western blotting. In the era of digital transformation and open access principles, an interactive cloud-based database called East-West Blot ( https://rancs-lab.shinyapps.io/WesternBlots ) is designed and developed. The online interactive subject-specific database built on the R shiny platform facilitates a systematic literature search on the specific subject matter, here set to western blot studies of protein regulation in the preclinical model of TBI. The tool summarizes the existing publicly available knowledge through a data visualization technique and easy access to the critical data elements and links to the study itself. The application compiled a relational database of PubMed-indexed western blot studies labeled under HHS public access, reporting downstream protein regulations presented by fluid percussion injury model of traumatic brain injury. The promises of the developed tool include progressing toward implementing the principles of 3Rs (replacement, reduction, and refinement) for humane experiments, cultivating the prerequisites of reproducible research in terms of reporting characteristics, paving the ways for a more collaborative experimental design in basic science, and rendering an up-to-date and summarized perspective of current publicly available knowledge.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    Studies of rare, but complex clinical conditions require multicenter cooperation. The International Society for Placenta accreta spectrum (IS-PAS) have established a secure web-based database to analyze pregnancies complicated by PAS. By repeated in-person meetings of the IS-PAS, a core dataset was established. Then, a custom-made, secure online database, capable of receiving strictly anonymized patient-related textual and imaging data and allowing statistical queries was designed, tested, amended and implemented. Between 2008 and 2019, 14 IS-PAS centers across Europe and one center in the USA contributed data for all their PAS cases, containing pregnancy data for a total of 442 pregnant women. Data were analyzed by a designated data analysis sub-group of the IS-PAS. Center characteristics are presented. Based on experiences with previous versions, our new online database now allows an all-encompassing data collection. It has shown its usefulness in the current analysis project.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Sci-hub)

  • 文章类型: Journal Article
    面对COVID-19全球医疗危机,全世界的科学家正在合作开发针对这种疾病的预防和治疗干预措施。抗体疗法在治疗COVID-19方面有着巨大的前景。2020年3月,中国抗体学会,与抗体协会合作,启动了“COVID-19抗体治疗追踪器”(“追踪器”)(https://chineseantibody.org/covid-19-track/)计划,以跟踪全球临床前和临床开发中基于抗体的COVID-19干预措施。这些数据是从公共领域收集的,并由志愿者持续验证。这里,我们提供探索性数据分析和可视化,以展示COVID-19抗体开发的最新趋势,基于截至2020年8月8日“跟踪器”中包含的150多个研究和开发计划和分子的数据。我们主要根据目标对数据进行分类,格式,发展现状,开发商和原产国。尽管在某些情况下细节有限,所有的抗SARS-CoV-2候选抗体似乎都靶向病毒刺突蛋白(S蛋白),大多数是全长单克隆抗体。目前临床试验中的大多数COVID-19抗体治疗候选药物都是针对病毒特异性蛋白以外的靶标的再用途药物,而这些病毒特异性治疗性抗体大多处于发现或临床前研究阶段。截至2020年8月8日,针对SARS-CoV-2S蛋白的八种候选抗体已进入临床研究,包括LY-CoV555、REGN-COV2、JS016、TY027、CT-P59、BRII-196、BRII-198和SCTA01。正在进行的SARS-CoV-2中和抗体的临床试验将有助于确定这些抗体作为治疗COVID-19和未来冠状病毒感染的新型治疗剂的效用。
    Facing the COVID-19 global healthcare crisis, scientists worldwide are collaborating to develop prophylactic and therapeutic interventions against the disease. Antibody therapeutics hold enormous promise for the treatment of COVID-19. In March 2020, the Chinese Antibody Society, in collaboration with The Antibody Society, initiated the \"COVID-19 Antibody Therapeutics Tracker\" (\"Tracker\") (https://chineseantibody.org/covid-19-track/) program to track the antibody-based COVID-19 interventions in preclinical and clinical development globally. The data are collected from the public domain and verified by volunteers on an ongoing basis. Here, we present exploratory data analyses and visualization to demonstrate the latest trends of COVID-19 antibody development, based on data for over 150 research and development programs and molecules included in the \"Tracker\" as of 8 August 2020. We categorized the data mainly by their targets, formats, development status, developers and country of origin. Although details are limited in some cases, all of the anti-SARS-CoV-2 antibody candidates appear to target the viral spike protein (S protein), and most are full-length monoclonal antibodies. Most of the current COVID-19 antibody therapeutic candidates in clinical trials are repurposed drugs aimed at targets other than virus-specific proteins, while most of these virus-specific therapeutic antibodies are in discovery or preclinical studies. As of 8 August 2020, eight antibody candidates targeting the SARS-CoV-2 S protein have entered clinical studies, including LY-CoV555, REGN-COV2, JS016, TY027, CT-P59, BRII-196, BRII-198 and SCTA01. Ongoing clinical trials of SARS-CoV-2 neutralizing antibodies will help define the utility of these antibodies as a new class of therapeutics for treating COVID-19 and future coronavirus infections.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Sci-hub)

       PDF(Pubmed)

  • 文章类型: Journal Article
    最近,免疫检查点抑制剂(ICIs)已成功用于治疗黑色素瘤.不幸的是,由于缺乏浸润的免疫细胞,许多乳腺癌(BC)患者对ICIs的反应较低.先前的研究表明,趋化因子-CXC受体(CXCRs)在白细胞浸润和促进癌细胞增殖中起关键作用,迁移,转移,和血管生成。然而,CXCRs在癌症-免疫周期中的基本功能尚不清楚.在这项研究中,我们首先发现,与正常组织相比,BC组织,尤其是基底样BC,使用UALCAN和TIMER数据库显示CXCR3/4/5/6/8的mRNA水平升高,但CXCR1/2/7的表达降低。有趣的是,研究发现,在BC免疫亚型的淋巴细胞耗竭中,CXCR3/4/5/6的mRNA水平降低。随后,不同CXCRs的功能富集分析表明,CXCR3/4/5/6与免疫相关生物学功能密切相关.因此,使用TIMER和TISIDB数据库的进一步分析表明,CXCR3/4/5/6的表达与BC中的肿瘤浸润淋巴细胞(TIL)和免疫检查点密切相关.最后,Kaplan-MeierPlotter分析表明,CXCR4的高mRNA表达预测无复发生存率(RFS)较差。而CXCR3/5/6在BC患者中显示更好的RFS。这些发现表明CXCR3/4/5/6与ICIs组合用于治疗BC的治疗价值。
    Recently, immune checkpoint inhibitors (ICIs) have been successfully used for treating melanoma. Unfortunately, many breast cancer (BC) patients show low response to ICIs due to the lack of infiltrating immune cells. Previous studies revealed that chemokine-CXC receptors (CXCRs) play a crucial role in leukocyte infiltration and promote cancer cell proliferation, migration, metastasis, and angiogenesis. However, the underlying functions of CXCRs in cancer-immunity cycle remain unclear. In this study, we firstly found that in comparison to normal tissues, BC tissues, especially basal-like BC, showed increased mRNA levels of CXCR3/4/5/6/8, but decreased CXCR1/2/7 expression using UALCAN and TIMER database. Interestingly, it\'s was found that the mRNA levels of CXCR3/4/5/6 were decreased in lymphocyte depleted of the BC immune subtype. Subsequently, functional enrichment analysis of distinct CXCRs indicated that CXCR3/4/5/6 were strongly associated to immune-related biological functions. Therefore, further analysis using TIMER and TISIDB database suggested that CXCR3/4/5/6 expression were strongly correlated with tumor-infiltrating lymphocytes (TILs) and immune checkpoints in BC. Finally, Kaplan-Meier Plotter analysis indicated that high mRNA expression of CXCR4 predicted worse relapse-free survival (RFS), whereas CXCR3/5/6 indicated better RFS in BC patients. These findings suggest a therapeutic value for CXCR3/4/5/6 in combination with ICIs for the treatment of BC.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Sci-hub)

  • 文章类型: Journal Article
    MedGen serves as a portal to information on genetic aspects of human health and disease. Created and maintained by the National Center for Biotechnology Information (NCBI), it aggregates clinically-relevant content from both NCBI and non-NCBI databases. MedGen summaries and curated links are designed to be particularly useful to health care professionals considering genetic aspects of patient care.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Sci-hub)

  • 文章类型: Journal Article
    Cardiovascular disease is characterized by its highest morbidity and mortality. One of the main pathological basis of this disease is the dysregulation of gene expression. Non-coding RNA (ncRNA) is a kind of functional RNA, which is transcript from DNA but not translated into proteins. More and more studies have established the important roles of ncRNAs, including transcription, RNA maturation, translation, protein degradation, and their involvement in the pathogenesis of diseases such as cancer and cardiovascular diseases. This chapter will focus on the biological functions of ncRNAs and their advances in cardiovascular disease. With the development of sequencing and computer technology, more and more databases can be easily obtained on the internet. In another part of this chapter, we will summarize some commonly used non-coding RNA databases, which can be easily and quickly used for relevant research.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

公众号